Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + simvastatin
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of erlotinib, an epidermal growth factor receptor (EGFR) inhibitor used for treating non-small-cell lung cancer and pancreatic cancer, and simvastatin, a statin medication used to lower blood cholesterol. Both drugs are major substrates of the CYP3A4 enzyme in the liver, creating potential for drug interactions. While simvastatin appears to have no significant effect on erlotinib pharmacokinetics in animal studies, there is a case report of rhabdomyolysis resulting from this combination in humans.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on erlotinib + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + simvastatin.